ARWR News 13.14 04/21/2014 19:56:29 Arrowhead Research Corp

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arrowhead Research Corp (ARWR) 13.14 $ARWR

35.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 16, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 3 weeks, Arrowhead Research has returned 35.34% as of today's recent price of $11.99.

Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Apr 16, 8:47AM CDT
Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 15, 12:55PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:

SmarTrend Watching for Potential Rebound in Shares of Arrowhead Research After 4.87% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:45PM CDT
Arrowhead Research (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $12.32 to a high of $13.76. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $12.84 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Why Arrowhead Research (ARWR) Stock is Down Today
at The Street - Mon Apr 14, 2:00PM CDT
Arrowhead Research (ARWR) dipped Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering...

Downtrend Call Working As Arrowhead Research Stock Falls 10.2% (ARWR)
Comtex SmarTrend(R) - Wed Apr 09, 9:20AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 weeks, Arrowhead Research has returned 10.17% as of today's recent price of $16.65.

A $1 Trillion Drug Market?
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 07, 5:30PM CDT
At the Barclays Global Healthcare Conference 2014 last month, Christopher Anzalone, president and CEO of Arrowhead Research   put up a slide suggesting that its hepatitis B drug would treat a $1 trillion market "even under conservative pricing...

Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Top Gainers under the Scanner -- Research on Trina Solar, JA Solar, Arrowhead Research, and King Digital Entertainment
PR Newswire - Wed Apr 02, 8:59AM CDT
The US markets saw a positive sentiment on Tuesday, April 01, 2014, with the NASDAQ Composite closing at 4,268.04, up 1.64%, the Dow Jones Industrial Average ending the session at 16,532.61, up 0.46% and the S&P 500 edging 0.70% higher to finish the trading session at 1,885.52. The session saw a positive impact from Consumer Discretionary, Information Technology and Industrials sectors along with a drag from Utilities, and Consumer Staples sectors. A number of stocks saw large movements, including Trina Solar Ltd (NYSE: TSL), JA Solar Holdings Co. Ltd (NASDAQ: JASO), Arrowhead Research Corp. (NASDAQ: ARWR) and King Digital Entertainment PLC (NYSE: KING). Free technical research on TSL, JASO, ARWR and KING can be downloaded upon signing up at:

Why Arrowhead Research Corp. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 01, 12:36PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Arrowhead Research , a clinical-stage...

Why Arrowhead Research (ARWR) Stock Is Up Today
at The Street - Tue Apr 01, 10:24AM CDT
Arrowhead Research (ARWR) is up 12% to $18.41 in trading Tuesday

Arrowhead Completes Enrollment of First Cohort in Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520
Business Wire - Tue Apr 01, 6:30AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The trial remains on schedule to meet the previously stated goal of completing dosing in the second quarter and releasing top line results in the third quarter.

3 Biotechs Falling Like a Knife: Arrowhead, Celldex, Receptos
George Budwell, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
By all accounts, biotech has had a rough week. The iShares Nasdaq Biotechnology Index is down more than 8%, and concerns over a bubble abound. Yet some companies are falling much faster than the broader sector. Are these companies becoming value...

Why Netflix, Arrowhead Research, and Trina Solar Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 24, 7:30PM CDT
The stock market finished lower on Monday, with initial enthusiasm giving way to concerns about valuations in the five-year-old bull market. Yet although most broad-based indexes escaped with only minimal losses, Netflix , Arrowhead Research ,...

Arrowhead Begins Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients
Business Wire - Mon Mar 24, 6:30AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that patient dosing has begun in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The study is planned to enroll up to 16 chronic HBV patients in two dose cohorts with patients receiving either ARC-520 or placebo in combination with entecavir. The study is designed to evaluate the depth and duration of hepatitis B surface antigen (HBsAg) decline, among other measures, in response to a single dose of ARC-520. The Company anticipates planned enrollment to be complete in the second quarter of 2014 and expects top line results to be released in the third quarter.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 26

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading

Top 5 Most Recently Viewed Articles

NuCana Discontinues Phase 2 Colorectal Cancer Study

Updated Category News Views 146

NuCana Provides Update on Phase 2 Randomized Colorectal Cancer Study NuTide:323 Study Discontinued Following Initial Analysis Ongoing Studies Show Promise with NUC-7738 and Pembrolizumab NuCana plc (NASDAQ: NCNA) has shared important updates about its clinical trials focused on innovative treatments for colorectal cancer. The company has made the decision to discontinue...

Continue Reading
Brøndbyernes IF Football Meeting - Key Highlights Recap

Updated Category News Views 179

Overview of the Annual General Meeting for Brøndbyernes IF Football A/S BRØNDBYERNES I.F. FODBOLD A/S CVR-nr. 83 93 34 10 This report summarizes the outcomes of the annual general meeting conducted by Brøndbyernes IF Football A/S. Key Date and Location The annual shareholders meeting took place, gathering stakeholders and shareholders at the club's headquarters. A...

Continue Reading
Uncovering the Wealth from Investing in BlackRock

Updated Category News Views 314

The Potential Growth of $1000 in BlackRock Investors often wonder how their money would grow over time if invested in strong companies. Recently, we looked into BlackRock, Inc., known by its stock ticker BLK. Over a span of 15 years, investing just $1000 into BlackRock stocks would yield an impressive value today. According to current evaluations, if you had made that...

Continue Reading
Zealand Pharma Advances Glepaglutide Approval for SBS Treatment

Updated Category News Views 267

Glepaglutide Submission to EMA Marks Significant Progress Zealand Pharma A/S, a pioneering biotechnology company, has recently shared exciting news about its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its innovative drug, glepaglutide. This long-acting GLP-2 analog is specifically designed for treating adults suffering from short...

Continue Reading
Seven Gables Real Estate Partners with Local Logic for Insights

Updated Category News Views 40

Seven Gables Real Estate Partners with Local Logic In a significant move that underscores their dedication to innovation, Seven Gables Real Estate has announced an exciting partnership with Local Logic, a leader in location intelligence. This collaboration is set to incorporate Local Logic's cutting-edge products—Local Content, Local Search, and NeighborhoodWrap—into...

Continue Reading